Alloy Antibody Discovery Services offers partners a modular campaign design that can meet their goals and budgets as they collaborate to discover the best antibodies with therapeutic potential.
BOSTON, Mass. – April 26, 2023 — Alloy Therapeutics, a biotechnology ecosystem company, announced the appointment of Kent Bondensgaard and John “Lippy” Lippincott as the latest members of its team, joining as Senior Vice President of Antibody Discovery Services and Senior Vice President of Therapeutic Discovery Strategies, respectively. In conjunction with the addition of these new team members, Alloy is also expanding its Antibody Discovery Services, offering partners the choice of two initial core discovery approaches to meet their specific research and development needs, with the option to invest in value-add service modules to further candidates toward clinical development. These updates underscore Alloy’s ongoing commitment to reinvest 100% of its revenue back into innovation and access to innovation.
Alloy Antibody Discovery Services campaigns now start with the choice of two rapid, high-throughput B cell-based antibody discovery approaches:
- SeqImmune™ is a sequence-first workflow that generates maximum initial antibody repertoire diversity, ideal for supporting campaigns in exploratory areas of biology without screening assays, benchmarks, or screening reagent(s).
- DeepImmune™ is a function-forward approach that focuses on early screening for functional attributes, specificity and blocking to support campaigns with well-defined therapeutic targets and available functional assays.
Regardless of which approach partners choose, they will receive Alloy’s world-class discovery process and data package which includes recombinant protein binding, cell binding, binding kinetics and affinity, biophysical characterization, and developability assessment data. Alloy Antibody Discovery Services offers partners a fully integrated workflow to discover therapeutic lead candidates, enabling them to expand their core discovery package with add-on capabilities spanning machine-learning enabled affinity maturation and engineering, bispecific engineering, functional studies through Alloy Translational Medicine Services, and antibody production. Every campaign can be flexibly priced according to the partner’s current budget and roadmap, with options for a modest upfront fee.
“With this Antibody Discovery Services expansion, Alloy is excited to welcome more collaborators by flexibly designing the discovery package needed to meet their goals and budget in advancing their therapeutic antibody pipeline,” said Kent Bondensgaard, Alloy’s new Senior Vice President of Antibody Discovery Services. “Joining Alloy represents a unique opportunity to further build out a dynamic, world-class biologics discovery organization that will efficiently advance novel therapeutics through continuously improving platform technologies and services, in support of both our external collaborators and new companies launched through Alloy’s venture studio, 82VS.”
Kent and Lippy’s addition to the growing Alloy team brings 40-plus years of collective experience in the development of biologics and the generation and characterization of antibodies. Kent most recently served as Vice President of Research at Kiniksa Pharmaceuticals and prior spent nearly 15 years in protein engineering and antibody technology for Novo Nordisk. Lippy is a veteran in the antibody discovery services field, previously leading therapeutic discovery and research operations for AlivaMab, Ablexis, and LakePharma, and establishing the hybridoma group at Pfizer’s San Diego site.
“I have been impressed with Alloy’s model of collaboration across the ecosystem and am thrilled to bring my passion for designing innovative therapeutic discovery organizations and technologies to Alloy’s broad portfolio of biologics services,” said Lippy, Alloy’s new Senior Vice President of Therapeutic Discovery Strategies. “Our diverse business model across modalities and partner organizations gives the collective drug discovery industry more opportunity to quickly advance novel therapeutics.”
Since Alloy’s launch in 2017 with its transgenic humanized mouse antibody discovery platform, the ATX-Gx™, the company has consistently developed and reintroduced enhanced protocols and technologies to make its partner campaigns more successful. Alloy now works with over 150 partners and across five additional, adjacent biologic modalities: T-cell Receptors (TCR mimics, TCRs, and CAR-T), genetic medicines, cell therapies, peptides, and drug delivery—and in 2021 launched Keyway TCR Discovery as the first fully-integrated drug discovery services organization for soluble TCR therapeutics.
“Kent and Lippy’s proven scientific expertise and longevity in the industry allow Alloy to increase our collaboration with our partners to help them to design and discover the ideal antibodies for their therapeutic applications,” said Alloy CEO and Founder Errik Anderson. “We recognize the challenging economic environment that drug discovery organizations are facing and have worked tirelessly to continue to build Alloy’s ecosystem to counteract the limits this places on our partners’ ability to advance new programs. Our breadth of capabilities and far-reaching time horizons allow us to continuously adapt to meet our partners’ needs, reinvest in adjacent areas, and lower the barriers to entry for new drug discovery programs.”
About Alloy Therapeutics
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery. Partners may access all current and future technologies through a discovery service relationship or for a flat annual fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.
Join the Alloy Therapeutics community by visiting alloytx.com, following Alloy on LinkedIn, scheduling a 15-minute introductory call with our team at alloytx.com/bd, or a 15-minute chat with Alloy’s Founder and CEO at alloytx.com/ceo.
###
Contact
Erin Glabets
Read more press coverage of the collaboration:
